Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IONIS-MAPTRx in Mild Alzheimer's Disease
NCT03186989Phase 1Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Oct 2017
- Primary completion
- May 2022
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 6
01
Overview
Phase 1, randomised, double-blind trial of biib080 in Alzheimer's disease (AD) (11 arms), sponsored by Ionis Pharmaceuticals. Primary endpoint: Number of Participants With Adverse Events That Are Related to Treatment With ISIS 814907 at Week 64. Started Oct 2017; status: completed.
02
Drugs
biib080
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03186989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03186989.